系统综述:药物治疗对X连锁低磷佝偻病患儿重要结局的疗效
本系统综述检索Embase、MEDLINE、Web of Science和Cochrane Central至2023年5月,纳入1项开放标签随机对照试验和1项事后研究比较布罗索尤单抗与常规治疗或无治疗,以及1项观察性研究评估常规治疗与无治疗。布罗索尤单抗可能预防下肢畸形并改善躯体健康生活质量(中等确定性),可能增加身高和慢性低磷血症相关症状负担(低确定性),可能增加治疗中出现的不良事件(中等确定性)和牙脓肿(低确定性)。常规治疗对最终身高的影响证据确定性极低。
要点
- 布罗索尤单抗对比常规治疗可能预防下肢畸形并改善躯体健康生活质量(中等确定性)。
- 布罗索尤单抗可能增加身高和慢性低磷血症相关症状负担(低确定性)。
- 布罗索尤单抗可能增加治疗中出现的不良事件(中等确定性)和牙脓肿(低确定性)。
核心结论
- 本综述表明布罗索尤单抗可能通过预防下肢畸形和改善躯体健康生活质量使儿童获益,并可能增加身高,但也可能增加不良事件。
- 本综述发现常规治疗对比无治疗对最终身高影响的证据有限。
- 需要进一步研究以了解儿童药物治疗的长期效果。
研究设计与样本
- 系统综述检索Embase、MEDLINE、Web of Science和Cochrane Central至2023年5月。
- 纳入随机对照试验和观察性研究,对象为18岁以下临床或遗传确诊的X连锁低磷佝偻病患者。
- 纳入比较布罗索尤单抗与无治疗或常规治疗(磷酸盐和活性维生素D)或评估常规治疗与无治疗的研究。
- 两名评价员独立确定纳入资格、提取数据并评估偏倚风险,采用GRADE方法评估证据确定性。
- 筛选4114条记录,评估254篇全文,最终纳入1项随机对照试验、1项事后研究和1项观察性研究。
主要发现
- 开放标签随机对照试验为高偏倚风险,证据确定性从中等到极低。
- 布罗索尤单抗对比常规治疗可能预防下肢畸形并改善躯体健康生活质量(中等确定性)。
- 布罗索尤单抗可能增加身高并增强慢性低磷血症相关症状负担(低确定性)。
- 布罗索尤单抗可能增加治疗中出现的不良事件(中等确定性)并可能增加牙脓肿(低确定性)。
- 一项评估常规治疗对比无治疗的观察性研究为高偏倚风险,关于常规治疗对最终身高影响的证据确定性极低。
局限性
- 开放标签随机对照试验为高偏倚风险。
- 证据确定性 ranging from moderate to very low。
- 评估常规治疗对比无治疗的观察性研究为高偏倚风险,提供极低确定性证据。
- 本综述发现常规治疗对比无治疗对最终身高影响的证据有限。
- 需要进一步研究以了解儿童药物治疗的长期效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the evidence addressing the management of X-linked hypophosphatemia (XLH) in children to inform treatment recommendations. METHODS: We searched Embase, MEDLINE, Web of Science, and Cochrane Central up to May 2023. Eligible studies included randomized controlled trials (RCTs) and observational studies of individuals younger than 18 years with clinically or genetically confirmed XLH. Manuscripts comparing burosumab to either no treatment or conventional therapy (phosphate and active vitamin D) or evaluating conventional therapy to no treatment were included. Two reviewers independently determined eligibility, extracted data, and assessed risk of bias (RoB). GRADE methodology was used to assess evidence certainty. RESULTS: We screened 4114 records and assessed 254 full texts. One RCT and one post hoc study proved eligible when comparing burosumab to conventional therapy or no treatment. The open-label RCT was at high RoB, with certainty of evidence ranging from moderate to very low. Burosumab, compared to conventional therapy, probably prevents lower limb deformity and improves physical health quality of life (QoL) (moderate certainty). Burosumab may increase height and enhance the burden of symptoms related to chronic hypophosphatemia (low certainty). Burosumab probably increases treatment-emergent adverse events (moderate certainty) and may increase dental abscesses (low certainty). One observational study assessing conventional therapy vs no treatment was at high RoB, providing very low certainty evidence regarding the impact of conventional therapy on final height. CONCLUSION: Our review indicates that burosumab likely provides benefits to children by preventing lower limb deformity and improving physical health QoL while potentially increasing height. However, burosumab may also increase adverse events. Our review found limited evidence regarding the impact of conventional therapy compared to no treatment on final height. Further research is required to understand the long-term effect of medical therapy in children.
引用
- Ali DS, Mirza RD, Hussein S, et al. Systematic Review: Efficacy of Medical Therapy on Outcomes Important to Pediatric Patients With X-Linked Hypophosphatemia. J Clin Endocrinol Metab. 2025. PMID: 39787354. doi:10.1210/clinem/dgaf011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。